Efficacy and Patient-Reported Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Aumolertinib as First-Line Therapy: A Real-World Study

    September 2024 in “ Frontiers in Pharmacology ”
    Hongxin Li, Zhao Wen, Caiyun Chang … Jisheng Li
    Studysummary In this real-world study, aumolertinib was found to improve patient-reported outcomes and maintain high disease control and objective response rates similar to those reported in the AENEAS trial for advanced NSCLC patients, supporting its use in first-line treatment.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on public-pages-files-2025.frontiersin.org →
    Discuss this study in the Community →